GLPG Articles, Galapagos NV - From 02/22/24

Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current f...

Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 C...

Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV ((Euronext &amp, NASDAQ:GLPG) today announced the successful completion of the tra...

Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos' point-of-care CAR-T product candidate in the San...

On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: ...

Strategic collaboration and licensing agreement further strengthens Galapagos' growing early-stage pipeline in oncology precision medicine C...

Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos' Chief Commerci...

Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV ((Euronext &amp, NASDAQ:GLPG) today announced that the first patient has been dos...

Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational i...

Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV ((Euronext &amp, NASDAQ:GLPG) today announced that it will host a Key Opinion Lead...